Indian Economy News

Bharat Biotech, University of Sydney ink MoU for vaccine research

  • IBEF
  • November 29, 2023

Bharat Biotech, a vaccine and bio-therapeutics producer, and the University of Sydney Infectious Diseases Institute (Sydney ID) inked a Memorandum of Understanding (MoU) to collaborate on vaccine development and the global fight against infectious illnesses.

The international agreement intends to create significant relationships between sectors and organisations to develop innovative techniques for dealing with future epidemics and infectious diseases. The collaboration also aims to combine the strengths of academia and industry in order to enhance vaccine and biotherapeutic technology.

Executive Chairman at Bharat Biotech, Mr. Krishna Ella stated, "This agreement reflects our ethos to facilitate collaborative research, foster innovation, and further advance the science of vaccine technology. Mutually, we are excited about the new opportunities to strengthen our shared vision, leverage the prowess of education, and research capabilities to help build a healthier universe and improve people's lives by developing safer vaccine platforms”.

The Deputy Director at Sydney ID, Mr. Jamie Triccas stated, "Together with Bharat Biotech International Limited, we aim to make a lasting impact on global health. The reputational and societal impacts of developing novel vaccines to eradicate human and animal diseases that are safe, affordable, and effective cannot be overstated".

The collaboration comes at a time when vaccines are widely acknowledged as the most effective and cost-effective option to safeguard billions of people worldwide. During the COVID-19 epidemic, India's skill in vaccine manufacture was crucial in satisfying more than 60% of the world's vaccine demand, producing more than 2.4 billion doses.

Bharat Biotech, based in Hyderabad, India, has a track record of invention, with over 145 global patents and a varied portfolio of vaccines and biotherapeutics. More than 9 billion vaccination doses have been distributed globally by the firm, including shots against rotavirus, Japanese encephalitis, rabies, chikungunya, zika, and cholera.

The University of Sydney Infectious Diseases Institute is a hub for infectious disease research, education, and advocacy. Its expertise directs global health programmes such as the creation of new vaccinations, research into antimicrobial resistance, and attempts to eradicate tuberculosis.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.